Shandong Xinhua Pharmaceutical Company Limited

SEHK:719 Rapporto sulle azioni

Cap. di mercato: HK$9.8b

Shandong Xinhua Pharmaceutical Gestione

Gestione criteri di controllo 3/4

Shandong Xinhua Pharmaceutical Il CEO è Wenhui Xu, nominato in Sep2022, e ha un mandato di 2.17 anni. la retribuzione annua totale è CN¥ 1.52M, composta da 93.8% di stipendio e 6.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.035% delle azioni della società, per un valore di HK$ 3.48M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.9 anni e 3.9 anni.

Informazioni chiave

Wenhui Xu

Amministratore delegato

CN¥1.5m

Compenso totale

Percentuale dello stipendio del CEO93.8%
Mandato del CEO2.2yrs
Proprietà del CEO0.04%
Durata media del management4.9yrs
Durata media del Consiglio di amministrazione3.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year

Jun 28
Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year

Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price

Jan 23
Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price

Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt

Mar 07
Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Nov 18
Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively

Jul 27
These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively

Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18

Jul 04
Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18

Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)

Mar 09
Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)

We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt

Dec 21
We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt

Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?

Apr 06
Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?

What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?

Mar 19
What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?

Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?

Feb 26
Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?

Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?

Feb 05
Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?

Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years

Jan 18
Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years

Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?

Dec 29
Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?

Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?

Dec 14
Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Nov 26
Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Wenhui Xu rispetto agli utili di Shandong Xinhua Pharmaceutical?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

CN¥449m

Jun 30 2024n/an/a

CN¥492m

Mar 31 2024n/an/a

CN¥487m

Dec 31 2023CN¥2mCN¥1m

CN¥497m

Sep 30 2023n/an/a

CN¥510m

Jun 30 2023n/an/a

CN¥486m

Mar 31 2023n/an/a

CN¥454m

Jan 01 2023n/an/a

CN¥411m

Sep 30 2022n/an/a

CN¥357m

Jun 30 2022n/an/a

CN¥343m

Mar 31 2022n/an/a

CN¥357m

Dec 31 2021CN¥1mn/a

CN¥349m

Sep 30 2021n/an/a

CN¥364m

Jun 30 2021n/an/a

CN¥353m

Mar 31 2021n/an/a

CN¥339m

Dec 31 2020CN¥829kn/a

CN¥325m

Compensazione vs Mercato: La retribuzione totale di Wenhui ($USD 210.10K ) è inferiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 487.68K ).

Compensazione vs guadagni: La retribuzione di Wenhui è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.


AMMINISTRATORE DELEGATO

Wenhui Xu (47 yo)

2.2yrs

Mandato

CN¥1,521,382

Compensazione

Mr. Wenhui Xu serves as Executive Director and General Manager of Shandong Xinhua Pharmaceutical Company Limited since October 27, 2022 and September 19, 2022 respectively. He served as the Deputy General...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Tongqing He
Chairman & Deputy GM3.9yrsCN¥1.61m0.043%
HK$ 4.2m
Wenhui Xu
GM & Executive Director2.2yrsCN¥1.52m0.035%
HK$ 3.5m
Ning Hou
CFO, Financial Controller & Executive Director10.6yrsCN¥1.28m0.048%
HK$ 4.7m
Zhonghui Zheng
Deputy General Manager7.7yrsCN¥1.41m0.043%
HK$ 4.2m
Changsheng Wei
Deputy GM & Manager of Administrative Personnel Departmentno dataCN¥1.41m0.035%
HK$ 3.5m
Xuesong Liu
Deputy General Manager2.2yrsCN¥831.80k0.013%
HK$ 1.3m
Changqiu Cao
Company Secretary27.3yrsCN¥446.80k0.029%
HK$ 2.9m
Zuxing Kou
Deputy General Manager2.2yrsCN¥1.10m0.011%
HK$ 1.1m
Haifeng Guo
Head of Accounting Departmentno dataNessun datoNessun dato
Xiaohong He
Chief of Finance Departmentno dataNessun datoNessun dato

4.9yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di 719 è considerato esperto (durata media dell'incarico 4.9 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Tongqing He
Chairman & Deputy GM3.9yrsCN¥1.61m0.043%
HK$ 4.2m
Wenhui Xu
GM & Executive Director2.1yrsCN¥1.52m0.035%
HK$ 3.5m
Ning Hou
CFO, Financial Controller & Executive Director2.1yrsCN¥1.28m0.048%
HK$ 4.7m
Zhichao Tao
Independent Supervisor22.4yrsCN¥24.00kNessun dato
Lie Xu
Non-Executive Director14.4yrsCN¥1.41m0.043%
HK$ 4.2m
Yanhua Hu
Employee Supervisor13.3yrsCN¥101.00kNessun dato
Guangcheng Pan
Independent Non-Executive Director3.9yrsCN¥100.00kNessun dato
Chengtong Liu
Chairman of Supervisory Committee3.9yrsNessun datoNessun dato
Jianwei Zhu
Independent Non-Executive Director3.9yrsCN¥100.00kNessun dato
Peixue Ling
Independent Non-Executive Director2.1yrsCN¥58.33kNessun dato
Chengyong Zhang
Non-Independent Directorless than a yearNessun datoNessun dato
Ching Ching Cheung
Independent Non-Executive Directorless than a yearNessun datoNessun dato

3.9yrs

Durata media

54yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 719 sono considerati esperti (durata media dell'incarico 3.9 anni).